The global Intravenous Immunoglobulin market size is expected to be worth around US$ xx billion by 2030, according to a new report by Vision Research Reports.
The global Intravenous Immunoglobulin market size was valued at US$ 19.09 billion in 2020 and is anticipated to grow at a CAGR of 17.1% during forecast period 2021 to 2030.
Growing geriatric population, rising prevalence of immunodeficiency diseases, increasing adoption of IVIG treatments, and rising use of off-label indications are the key drivers of the market. Rising number of patients with immunodeficiency disorders is the primary cause for the development of IVIG preparations.
According to the W.H.O, currently, there are over 50 different Primary Immune Deficiency (PID’s) such as specific antibody deficiency, X-lined hypo-gamma-globulinemia, and others. PIDs include 176 different types of rare hereditary disorders. According to the U.S. National Library of Medicine and National Institute of Health, approximately 6 million patients are suffering from PID worldwide. Growing incidences of these diseases are expected to boost the demand for immunoglobulin therapies over the forecast period.
The demand for IVIG therapies for the treatment of acquired and primary immunodeficiency diseases is increasing as it is the most effective & the only available treatment option. Moreover, sedentary lifestyle habits, including consumption of saturated fats salt, & sugars, less physical activities, and high alcohol consumption have led to an increase in the prevalence of these diseases. Rising prevalence of lifestyle-associated disorders such as obesity & antibody deficiency disorders are the factors expected to drive the growth.
Hypogammaglobulinemia dominated the application segment at 21.1% in 2014. This can be attributed to the owing to increasing incidences of primary immunodeficiency diseases (PID) worldwide. It is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs). As per the CDC in 2012, the incidence rate of hypogammaglobulinemia across the globe was around 2 per 100,000 populations every year and is expected to rise in the near future. Increasing incidence of immunodeficiency disorders coupled with the high adoption of IVIG therapies is expected to drive the segment growth in the near future.
Chronic Inflammatory demyelinating polyneuropathy (CIDP) segment held the second-largest share of the IVIG market on the basis of application. It is usually found in patients with diabetes mellitus. The treatment of CIPD involves the use of immunosuppressive drugs, steroids, and plasmapheresis. IVIG is an effective and long-lasting alternative to these methods. The associated benefits such as safety, minimally invasive and user-friendly treatment option are the factors contributing towards the development of the industry.
Immunodeficiency diseases accounted for the third-largest share of the industry owing to the increasing incidence of primary and acquired immunodeficiency diseases (PID & AID). PID & AID need to be treated with IV antibiotics to clear the infections. IVIG replacement therapy is the best available alternative for the treatment of immunodeficiency diseases. Hence the business is expected to show steady growth in the coming years.
Kawasaki disease segment is expected to exhibit lucrative growth owing to rising incidences of Kawasaki disease in children and rising demand for IVIG procedures for its treatment. The alternative for IVIG therapy is steroids which have more side effects; hence the penetration of IVIG therapies for the treatment of Kawasaki disease is expected to grow in the coming years. Moreover, factors such as increasing patient awareness levels and rising incidence of antibody deficiency diseases, and are expected to boost the demand for IVIG therapy consequentially driving the growth of this segment.
Intravenous administration accounted for the largest revenue share in 2014, of the route of administration segment. The substantial share is a direct consequence of high usage of intravenous immunoglobulins in a wide range of immunology applications. Intravenous administration of IVIGs is the primary line of treatment for immunodeficiency illness.
Moreover, increasing number of intravenous product approvals and clinical trials for new clinical applications is anticipated to provide potential growth opportunities for the industry. Increasing healthcare expenditure and growing awareness pertaining to autoimmune diseases are also anticipated to further facilitate the growth of this segment.
Subcutaneous administration is expected to grow at an exponential rate of 9.8% over the forecast period. Increasing incorporation of subcutaneous IGs in the treatment of PIDs is anticipated to provide growth potential to this segment. This can be attributed to potential advantages associated with subcutaneous administration such as quick response and fewer side effects.
The segment growth is also driven by key contributing factors such as increasing usage and preference of subcutaneous immunoglobulin in home based self-infusion immunotherapy. The extensive product pipeline of subcutaneously administered IVIGs is anticipated to further contribute towards the growth of this segment.
North America dominated the overall market in terms of revenue in 2014 at 47.7%. Increasing level of awareness pertaining to products involved in the treatment of immunodeficiency diseases, rising inclination of clinicians towards these therapies, and growing healthcare expenditure are the key factors contributing towards the market growth.
Changing lifestyle and rising geriatric population prone to chronic diseases are some of the factors contributing to the growth of this industry. In addition, increasing incidences of PID is expected to present this market with future growth opportunities. According to the American Autoimmune Related Disease Association Inc. (AARDA), near about 50 million Americans were suffered from autoimmune diseases in the year 2012 and the number is expected to grow over the forecast period.
Asia Pacific is anticipated to exhibit lucrative growth over the forecast period as a consequence of increasing awareness and potential opportunities for adoption of immunoglobulin based therapies for the treatment of primary immune deficiencies coupled with growing geriatric population.
Biotest AG, Baxter International Inc., Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma, and BDI Pharma Inc.
Chronic Lymphocytic Leukemia
Multifocal motor neuropathy
Route of Administration Outlook
The Middle East and Africa
The Intravenous Immunoglobulin market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Intravenous Immunoglobulin market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Intravenous Immunoglobulin market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Intravenous Immunoglobulin market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Intravenous Immunoglobulin market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Intravenous Immunoglobulin capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Intravenous Immunoglobulin by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Intravenous Immunoglobulin market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Intravenous Immunoglobulin market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Intravenous Immunoglobulin market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Intravenous Immunoglobulin industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Intravenous Immunoglobulin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Intravenous Immunoglobulin market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Intravenous Immunoglobulin market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Intravenous Immunoglobulin market. These factors have benefited the growth of the global market for Intravenous Immunoglobulin. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Intravenous Immunoglobulin. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Intravenous Immunoglobulin are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
To strategically profile the key players and comprehensively analyze their growth strategies.